Guselkumab: all 80 studies that test it

Page 1 of 1. Open to participants first (19), then studies with results posted, then the rest; newest registration first within each.

• A Study to Investigate How Well an Intracolonic Formulation of Two Monoclonal Antibodies is Tolerated in Healthy Participants and the Ability for the Antibodies to be Taken up by the Body Via the ColonNot yet recruitingNCT07788807Phase 1
• A Remotely Conducted Study to Assess Concentration of TREMFYA in Breast Milk of Lactating Women Who Are Receiving TREMFYA TherapeuticallyRecruitingNCT07654751Phase 4
• Optimal Care With Guselkumab in Crohn's Disease / OPTIM Study A Prospective Open Label Interventional, Multicenter StudyRecruitingNCT07616687Phase 4
• A Study to Evaluate Comparative Efficacy and Safety of Guselkumab in High-dose and Extended-interval Versus Standard-dose in Chinese Participants of Moderate-to-severe Plaque PsoriasisRecruitingNCT07532486Not applicable
• A Study of Guselkumab Versus Risankizumab in Participants With Moderately to Severely Active Crohn's DiseaseRecruitingNCT07499232Phase 3
• Utilization of a Microdevice for Psoriasis and Atopic DermatitisNot yet recruitingNCT07352566Phase 4
• A Study to Evaluate the Efficacy of Guselkumab in Chinese Participants With Crohn's Disease (CD)RecruitingNCT07310095Phase 4
• A Study of Guselkumab Administered Subcutaneously in Treatment of Indian Participants With Psoriatic Arthritis (PsA)RecruitingNCT07141004Phase 4
• Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder ArthroplastyRecruitingNCT07138898Phase 2
• Potential Role of Guselkumab in Modulating PAIN Perception and Related Gene Pathways: a Proof-of-concept Study.RecruitingNCT06974474Phase 4
• A Long-term Extension (LTE) Study of Guselkumab in Pediatric ParticipantsRecruitingNCT06663332Phase 3
• Efficacy of Guselkumab in Treating Hailey Hailey DiseaseRecruitingNCT06651489Phase 2
• Elucidating Shared Mechanisms Contributing to NAFLD and PsA Disease Severity With Guselkumab TherapyRecruitingNCT06586281Not applicable
• Proactive TDM Versus Standard Use of Biologics in PsoriasisRecruitingNCT06398106Phase 4
• A Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Crohn's DiseaseRecruitingNCT05923073Phase 3
• Immune Spatial Features of Guselkumab Cutaneous ResponseRecruitingNCT05858632Phase 4
• Guselkumab vs Golimumab in PsA TNF Inadequate Responder PatientsRecruitingNCT05669833Phase 3
• Immunoclassification of Psoriasis: a Strategy for Precision MedicineRecruitingNCT05503875Not applicable
• Multi-Center PAMPA StudyRecruitingNCT05004727Phase 4
• Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque PsoriasisCompletedNCT06039189Phase 3Results posted
• A Study of Guselkumab for the Treatment of Participants With Crohn's Disease After Surgical ResectionTerminatedNCT05784129Phase 3Results posted
• A Study of Guselkumab Therapy in Participants With Moderately to Severely Active Ulcerative ColitisActive, not recruitingNCT05528510Phase 3Results posted
• Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/or Scalp PsoriasisCompletedNCT05272150Phase 3Results posted
• A Study of Guselkumab Subcutaneous Therapy in Participants With Moderately to Severely Active Crohn's DiseaseActive, not recruitingNCT05197049Phase 3Results posted
• Effect of Guselkumab on Cardiovascular Risk Surrogate Markers in Participants With Moderate to Severe Plaque PsoriasisTerminatedNCT05125679Phase 4Results posted
• Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha AgentCompletedNCT04936308Phase 3Results posted
• A Study of Guselkumab in Participants With Active Psoriatic ArthritisActive, not recruitingNCT04882098Phase 3Results posted
• A Study of Guselkumab in Participants With Systemic SclerosisCompletedNCT04683029Phase 2Results posted
• Guselkumab ImmunogeneticsCompletedNCT04645355Phase 4Results posted
• A Study to Evaluate Guselkumab for the Treatment of Participants With New-onset or Relapsing Giant Cell ArteritisTerminatedNCT04633447Phase 2Results posted
• A Study of Guselkumab in Participants With Moderately to Severely Active Crohn's DiseaseCompletedNCT04397263Phase 3Results posted
• A Study of Guselkumab in Participants With Active Lupus NephritisTerminatedNCT04376827Phase 2Results posted
• A Study of Guselkumab in Participants With Moderately to Severely Active Ulcerative ColitisActive, not recruitingNCT04033445Phase 2/3Results posted
• Guselkumab in the Treatment of Pityriasis Rubra Pilaris (PRP)CompletedNCT03975153Phase 2Results posted
• A Study to Evaluate Further Therapeutic Strategies With Guselkumab in Participants With Moderate-to-Severe Plaque-Type PsoriasisCompletedNCT03818035Phase 3Results posted
• A Study of Efficacy and Safety of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative ColitisCompletedNCT03662542Phase 2Results posted
• A Study to Evaluate the Efficacy, Safety, and Tolerability of Guselkumab for the Treatment of Participants With Moderate to Severe Hidradenitis Suppurativa (HS)CompletedNCT03628924Phase 2Results posted
• A Study of Ixekizumab (LY2439821) Compared to Guselkumab in Participants With Moderate-to-Severe Plaque PsoriasisCompletedNCT03573323Phase 4Results posted
• A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's DiseaseActive, not recruitingNCT03466411Phase 2/3Results posted
• A Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Participants With Active Psoriatic Arthritis Including Those Previously Treated With Biologic Anti -Tumor Necrosis Factor (TNF) Alpha Agent(s)CompletedNCT03162796Phase 3Results posted
• A Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Participants With Active Psoriatic ArthritisCompletedNCT03158285Phase 3Results posted
• A Study to Evaluate the Comparative Efficacy of CNTO 1959 (Guselkumab) and Secukinumab for the Treatment of Moderate to Severe Plaque-type PsoriasisCompletedNCT03090100Phase 3Results posted
• A Study to Compare the Efficacy of Guselkumab to Fumaric Acid Esters for the Treatment of Participants With Moderate to Severe Plaque PsoriasisCompletedNCT02951533Phase 3Results posted
• Efficacy and Safety Study of Guselkumab in the Treatment of Participants With Moderate to Severe Plaque-Type PsoriasisCompletedNCT02905331Phase 3Results posted
• An Efficacy and Safety of Guselkumab in Participants With Palmoplantar PustulosisCompletedNCT02641730Phase 3Results posted
• An Efficacy and Safety of CNTO 1959 (Guselkumab) in Participants With Moderate to Severe Plaque-type PsoriasisCompletedNCT02325219Phase 3Results posted
• Efficacy and Safety Study of Guselkumab in the Treatment of Participants With Active Psoriatic Arthritis (PsA)CompletedNCT02319759Phase 2Results posted
• A Study of Guselkumab in Participants With Moderate to Severe Plaque-type Psoriasis and an Inadequate Response to UstekinumabCompletedNCT02203032Phase 3Results posted
• A Study of the Effectiveness and Safety of Ustekinumab (STELARA) and CNTO 1959 Administered Under the Skin of Patients With Active Rheumatoid Arthritis, Despite Existing Methotrexate TherapyCompletedNCT01645280Phase 2Results posted
• A Study to Evaluate CNTO 1959 in the Treatment of Patients With Moderate to Severe Plaque-type PsoriasisCompletedNCT01483599Phase 2Results posted
• Guselkumab in the Treatment of Adults With Pyoderma Gangrenosum (PG)Active, not recruitingNCT06563323Phase 2
• Transmural Healing and Disease-Modifying Effect of Guselkumab in Crohn's Disease PatientsActive, not recruitingNCT06408935Phase 3
• A Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Ulcerative ColitisActive, not recruitingNCT06260163Phase 3
• Using a Contact Dermatitis Model With Biologic Medications to Study Skin InflammationActive, not recruitingNCT05535738Phase 2/3
• A Study of Guselkumab in Participants With Fistulizing, Perianal Crohn's DiseaseActive, not recruitingNCT05347095Phase 3
• A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative ColitisActive, not recruitingNCT05242484Phase 2
• A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's DiseaseActive, not recruitingNCT05242471Phase 2
• A Study of Ustekinumab or Guselkumab in Pediatric Participants With Active Juvenile Psoriatic ArthritisCompletedNCT05083182Phase 3
• A Study of Guselkumab and Risankizumab in Healthy Participants and Participants With Psoriatic ArthritisTerminatedNCT05083078Phase 1
• A Study of Guselkumab Administered Subcutaneously in Bio-naive Participants With Active Psoriatic Arthritis Axial DiseaseActive, not recruitingNCT04929210Phase 4
• A Study of Guselkumab (TREMFYA) in Chinese Participants With Moderate to Severe Plaque PsoriasisCompletedNCT04914429Phase 4
• Guselkumab (Anti-IL 23 Monoclonal Antibody) for Alcohol Associated Liver DiseaseCompletedNCT04736966Phase 1
• A Study of Guselkumab in Adult Participants With Celiac DiseaseWithdrawnNCT04704843Phase 1
• A Study of Intravenous Formulation of Guselkumab Using Prefilled Syringes and Final Vialed Product in Healthy ParticipantsCompletedNCT04617691Phase 1
• An Explorative Psoriasis Biomarker StudyTerminatedNCT04394936Not applicable
• Dose Reduction of IL17 and IL23 Inhibitors in PsoriasisCompletedNCT04340076Phase 4
• A Study of Subcutaneously-administered Guselkumab Delivered by 3 Different Devices in Healthy ParticipantsCompletedNCT04147338Phase 1
• Biomarkers in Participants With Hidradenitis Suppurativa Receiving Guselkumab.WithdrawnNCT04084665Early Phase 1
• Guselkumab for Hidradenitis Suppurativa, a Mode of Action Study.CompletedNCT04061395Phase 2
• Study of Guselkumab and Ustekinumab Following a Single Intravenous or Subcutaneous Administration in Healthy Chinese ParticipantsCompletedNCT04030533Phase 1
• A Study of Guselkumab for the Treatment of Palmoplantar-non-Pustular PsoriasisCompletedNCT03998683Phase 3
• A Study of Guselkumab in Participants With Active Psoriatic Arthritis and an Inadequate Response to Anti-Tumor Necrosis Factor Alpha (Anti-TNF Alpha) TherapyCompletedNCT03796858Phase 3
• A Study of Guselkumab in Participants With Familial Adenomatous PolyposisCompletedNCT03649971Phase 1
• A Study to Assess the Safety, Tolerability and Pharmacokinetics of Guselkumab Following a Single Intravenous Administration in Healthy Japanese ParticipantsCompletedNCT03536325Phase 1
• A Study to Characterize the Elimination of Guselkumab Glycoform Variants in Healthy ParticipantsCompletedNCT02570373Phase 1
• Pharmacokinetic Study to Evaluate the Effect of a Single Dose of Guselkumab (CNTO 1959) on CYP 450 Enzyme Activities After Subcutaneous Administration in Participants With PsoriasisCompletedNCT02397382Phase 1
• An Efficacy and Safety Study of CNTO1959 (Guselkumab) in the Treatment of Participants With Generalized Pustular Psoriasis or Erythrodermic PsoriasisCompletedNCT02343744Phase 3
• A Study to Assess the Pharmacokinetic Comparability of Guselkumab (CNTO1959) When Delivered by 2 Different Devices and as 2 Formulations in Healthy ParticipantsCompletedNCT01866007Phase 1
• A Study of the Efficacy, Safety and Tolerability of CNTO 1959, a Human Anti-IL 23 Monoclonal Antibody in Participants With Palmoplantar PustulosisCompletedNCT01845987Phase 2
• A Study of the Safety, Tolerability, Pharmacokinetics (What the Body Does to the Drug), and Pharmacodynamics (What the Drug Does to the Body) of CNTO 1959 Following a Single Subcutaneous (Under the Skin) Administration in Japanese Participants With Moderate to Severe Plaque PsoriasisCompletedNCT01484587Phase 1

← Guselkumab overview